24,211 Shares in Danaher Corporation $DHR Bought by AG2R LA Mondiale Gestion D Actifs

Key Points

• AG2R LA Mondiale Gestion D Actifs purchased 24,211 shares of Danaher Corporation, valued at approximately $4.6 million, during the first quarter.
• Danaher recently announced a $0.32 quarterly dividend, to be paid on October 31st, with an annualized yield of 0.7% and a payout ratio of 27.23%.
• The company reported earnings per share (EPS) of $1.80 for the last quarter, surpassing expectations and reflecting a year-over-year revenue increase of 3.4%.

AG2R LA Mondiale Gestion D Actifs bought a new position in shares of Danaher Corporation (NYSE:DHR - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 24,211 shares of the conglomerate's stock, valued at approximately $4,598,000.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Voya Investment Management LLC lifted its stake in shares of Danaher by 1.1% in the first quarter. Voya Investment Management LLC now owns 886,002 shares of the conglomerate's stock valued at $181,630,000 after buying an additional 9,926 shares in the last quarter. Howe & Rusling Inc. lifted its stake in shares of Danaher by 103.7% in the first quarter. Howe & Rusling Inc. now owns 31,226 shares of the conglomerate's stock valued at $6,401,000 after buying an additional 15,897 shares in the last quarter. Guinness Asset Management LTD lifted its stake in shares of Danaher by 5.3% in the first quarter. Guinness Asset Management LTD now owns 171,960 shares of the conglomerate's stock valued at $35,253,000 after buying an additional 8,624 shares in the last quarter. eCIO Inc. bought a new position in shares of Danaher in the first quarter valued at $131,000. Finally, Osterweis Capital Management Inc. lifted its stake in shares of Danaher by 26.0% in the first quarter. Osterweis Capital Management Inc. now owns 128,535 shares of the conglomerate's stock valued at $26,350,000 after buying an additional 26,494 shares in the last quarter. 79.05% of the stock is owned by institutional investors.

Danaher Stock Performance

NYSE DHR opened at $195.23 on Friday. The company's 50 day moving average is $201.47 and its 200-day moving average is $199.04. The firm has a market cap of $139.79 billion, a P/E ratio of 41.54, a price-to-earnings-growth ratio of 2.69 and a beta of 0.75. Danaher Corporation has a 12-month low of $171.00 and a 12-month high of $279.90. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, beating the consensus estimate of $1.64 by $0.16. The company had revenue of $5.94 billion during the quarter, compared to analysts' expectations of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. Danaher's revenue for the quarter was up 3.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Sell-side analysts predict that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend is Friday, September 26th. Danaher's payout ratio is currently 27.23%.

Insider Buying and Selling

In other Danaher news, Director Teri List sold 2,778 shares of the business's stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the transaction, the director owned 20,751 shares of the company's stock, valued at $4,379,706.06. The trade was a 11.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 11.10% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on DHR shares. Wells Fargo & Company dropped their price target on shares of Danaher from $210.00 to $205.00 and set an "equal weight" rating on the stock in a research report on Wednesday, July 23rd. UBS Group lowered their price objective on shares of Danaher from $240.00 to $225.00 and set a "buy" rating on the stock in a research report on Wednesday, July 23rd. Guggenheim reaffirmed a "buy" rating and issued a $250.00 price objective on shares of Danaher in a research report on Wednesday, July 23rd. Wall Street Zen raised shares of Danaher from a "hold" rating to a "buy" rating in a research report on Friday, June 27th. Finally, Royal Bank Of Canada set a $241.00 price objective on shares of Danaher in a research report on Tuesday, September 2nd. Seventeen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, Danaher currently has an average rating of "Moderate Buy" and a consensus target price of $246.35.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.